

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application.

1. (Currently amended) A tablet for use in a drip tray, the tablet including:

an excipient selected so that the tablet will not fully dissolve in water at ambient temperature
for a period of at least three months;

at least 500 ppm of a biocide;

at least one enzyme; and

enzyme preserving means for maintaining enzyme activity in a moist environment;

wherein the enzyme preserving means is a boron compound and wherein the tablet inhibits
biofilm growth.
2. (Original) A tablet according to claim 1 wherein the excipient is selected such that the tablet
will not fully dissolve in water at ambient temperature for a period of at least 6 months.
3. (Original) A tablet according to claim 1 wherein the excipient is selected such that the tablet
will not fully dissolve in water at ambient temperature for a period of at least 12 months.
4. (Currently amended) A tablet according to claim 1 wherein the excipient includes one or
more compounds selected from the group consisting of poly vinyl alcohols, ~~high molecular
weight~~ polyethylene glycols, ~~high molecular weight~~ polypropylene glycols, esters or partial
esters of polyethylene glycols or of polypropylene glycols, and ~~high molecular weight~~
thermoplastic surfactants.
5. (Currently amended) A tablet according to claim 4 wherein the ~~excipient includes one or
more high molecular weight~~ thermoplastic surfactant is selected from the group consisting of
polyoxyethylene condensates, polyoxypropylene condensates, polyoxyethylene-
polyoxypropylene copolymers with hydrophobes, and combinations thereof.
6. (Previously presented) A tablet according to claim 1 wherein the at least one enzyme is
selected from the group consisting of proteolytic and hydrolase enzymes.
7. (Cancelled) .

8. (Currently amended) A tablet according to claim 17 wherein the boron compound is present in a concentration sufficient to maintain enzyme activity for at least three months during use.
9. (Previously presented) A tablet according to claim 1 wherein the excipient comprises 2% to 95% by weight of the tablet.
10. (Previously presented) A tablet according to claim 9 wherein the excipient comprises 10% to 80% by weight of the tablet.
11. (Previously presented) A tablet according to claim 10 wherein the excipient comprises 20% to 60% by weight of the tablet.
12. (Previously presented) A tablet according to claim 1 wherein the at least one enzyme comprises up to 20% by weight of the tablet.
13. (Previously presented) A tablet according to claim 12 wherein the at least one enzyme comprises up to 10% by weight of the tablet
14. (Previously presented) A tablet according to claim 13 wherein the at least one enzyme comprises up to 5% by weight of the tablet.
15. (Previously presented) A tablet according to claim 14 wherein the at least one enzyme comprises up to 3% by weight of the tablet.
16. (Previously presented) A tablet according to claim 1 wherein the enzyme preserving means is present in an amount of from 0.1% to 10% by weight of the tablet.
17. (Previously presented) A tablet according to claim 16 wherein the enzyme preserving means is present in an amount of from 0.1% to 3% by weight of the tablet.
18. (Previously presented) A tablet according to claim 1 wherein the biocide is present in an amount of from 0.1% to 20% by weight of the tablet.
19. (Previously presented) A tablet according to claim 18 wherein the biocide is present in an amount of from 0.5% to 10% by weight of the tablet.
20. (Previously presented) A tablet according to claim 19 wherein the biocide is present in an amount of from 1% to 5% by weight of the tablet.

21. (Previously presented) A tablet according to claim 1 further including a surfactant.
22. (Previously presented) A tablet according to claim 1 when made in a tablet press.
23. (Previously presented) A tablet according to claim 1 when made by a process including the step of moulding.
24. (Previously presented) A tablet according to claim 1 when made by a process including the step of extrusion.
25. (Previously presented) A tablet according to claim 1 that is a slow release encapsulated tablet.
26. (Withdrawn) A method for inhibiting the growth of a biofilm in a drip tray or the like, including the step of adding to the tray, a tablet including:

an excipient selected so that the tablet will not fully dissolve in water at ambient temperature
for a period of at least three months;
at least 500 ppm of a biocide;
at least one enzyme; and
enzyme preserving means for maintaining enzyme activity in a moist environment.
- 27–28. (Cancelled)
29. (New) A tablet according to claim 1 wherein the enzyme preserving means is borax.